Key facts
- This page summarizes William Lis's Form 4 filing for Jasper Therapeutics, Inc. (JSPR).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 28 Jun 2022, 16:01.
William Lis - 24 Jun 2022 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)
- Reporting relationship
- Director
- Issuer ticker
- JSPR
- Reported as of
- 24 Jun 2022
- Net transaction value
- -$101,434
- SEC form
- 4
- Accepted by SEC
- 28 Jun 2022, 16:01:39 UTC
- Prior SEC filing
- 23 Mar 2022
- Next SEC filing
- 13 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Jeet Mahal, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William Lis filed Form 4 for Jasper Therapeutics, Inc. (JSPR) on 28 Jun 2022.
Change
- Previous filing in this sequence was filed on 23 Mar 2022.
- Current net transaction value: -$101,434.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JSPR
transaction
Voting Common Stock
Sale
- Transaction value
- $50,030
- Shares
- -24,743
- Change %
- -28%
- Price
- $2.02
- Shares after
- 65,229
- Date
- 24 Jun 2022
- Ownership
- Direct
- Footnotes
- F1, F2
JSPR
transaction
Voting Common Stock
Sale
- Transaction value
- $51,404
- Shares
- -24,743
- Change %
- -38%
- Price
- $2.08
- Shares after
- 40,486
- Date
- 27 Jun 2022
- Ownership
- Direct
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.88 to $2.24, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.86 to $2.30, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
SEC remarks
Executive Chairman of the Board